'Blow-out' smoker's lung treatment data boosts drugmaker Sanofi | Business

  • 📰 News24
  • ⏱ Reading Time:
  • 42 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 20%
  • Publisher: 80%

مصر أخبار أخبار

مصر أحدث الأخبار,مصر عناوين

Sanofi's asthma drug Dupixent met all targets in a trial to treat 'smoker's lung', potentially adding billions to the French drugmaker's growth prospects, but also underscoring a heavy reliance on its bestseller. | News24_Business

Sanofi's asthma drug Dupixent met all targets in a trial to treat"smoker's lung", potentially adding billions to the French drugmaker's growth prospects, but also underscoring a heavy reliance on its bestseller.

The French group's stock was up 4.5% at 0818 GMT, reaching a seven-month high and far outperforming a 0.5% decline in the STOXX Europe 600 Health Care index. JP Morgan analyst Richard Vosser said the trial update had"blow-out data" in store for investors, and that market consensus for 2027 Dupixent sales of 15.7 billion euros would likely be topped-up by between 1 and 2 billion euros.

The anti-inflammatory drug accounted for 8.3 billion euros, or more than 19% of the French group's overall sales of 43 billion euros, last year. That was a currency-adjusted increase of 44% from a year earlier.The companies said that full efficacy and safety results would be presented later. They added a second late-stage COPD Dupixent trial was ongoing, with the first data read-out expected next year.

لقد قمنا بتلخيص هذا الخبر حتى تتمكن من قراءته بسرعة. إذا كنت مهتمًا بالأخبار، يمكنك قراءة النص الكامل هنا. اقرأ أكثر:

 /  🏆 4. in EG
 

شكرًا لك على تعليقك. سيتم نشر تعليقك بعد مراجعته.

_Business I know we all probably might have heard about Bitcoin but don't know how it works, I tried it in a week ago by a woman who recommended me to Thomas__Lawson on Twitter he guides me through the process and I made a lot of money and now I'm recommending her to y'all Thomas__Lawson

مصر أحدث الأخبار, مصر عناوين